Skip to main content

Advertisement

SpringerLink
Log in

The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

We investigated whether the concomitant use of meloxicam and methotrexate might induce kidney and liver damages in patients with rheumatoid arthritis (RA). We enrolled 101 RA patients with normal kidney and liver functions taking meloxicam and methotrexate concomitantly for more than 6 months. Blood and urine tests were performed. Estimated glomerular filtration rate (eGFR) and liver stiffness measurement (LSM) were used for evaluating silent kidney and liver damages. Ultrasonography was also performed to exclude structural abnormalities. We adopted 90 mL/min/1.73 mm2 and 5.3 kPa as the cutoff for an abnormal eGFR and LSM. The mean age (85 women) was 51.9 years. The mean eGFR was 97.0 mL/min/1.73 m2 and the mean LSM was 4.7 kPa. The mean weekly dose of methotrexate was 13.4 mg. The mean weekly dose of methotrexate did not correlate with eGFR or LSM. Neither the cumulative dose of meloxicam or methotrexate nor the mean weekly dose of methotrexate showed the significant odds ratio or relative risk for abnormal eGFR and LSM values. The use of higher-dose MTX, above 15 mg per week, with meloxicam did not significantly increase the risk for abnormal LSM and eGFR (RR = 2.042, p = 0.185; RR = 0.473, p = 0.218). The concomitant use of meloxicam and MTX did not clearly increase the risk of silent kidney or liver damage in RA patients with normal laboratory results taking MTX and meloxicam concurrently for over 6 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344(12):907–916

    Article  CAS  PubMed  Google Scholar 

  2. Paulus HE (1990) The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum 33(1):113–120

    Article  CAS  PubMed  Google Scholar 

  3. Phillips DC, Woollard KJ, Griffiths HR (2003) The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 138(3):501–511

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Nesher G, Osborn TG, Moore TL (1996) In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 14(4):395–399

    CAS  PubMed  Google Scholar 

  5. Riksen NP, Barrera P, van den Broek PH, van Riel PL, Smits P, Rongen GA (2006) Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 65(4):465–470

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Sfikakis PP (2010) The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010(11):180–210

    Article  Google Scholar 

  7. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, Anderson L, Block S, Small R, Wolfe F et al (1991) Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study. J Rheumatol 18(3):334–338

    CAS  PubMed  Google Scholar 

  8. Schnabel A, Gross WL (1994) Low-dose methotrexate in rheumatic diseases–efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 23(5):310–327

    Article  CAS  PubMed  Google Scholar 

  9. Kremer JM, Petrillo GF, Hamilton RA (1995) Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 22(1):38–40

    CAS  PubMed  Google Scholar 

  10. Kremer JM, Hamilton RA (1995) The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 22(11):2072–2077

    CAS  PubMed  Google Scholar 

  11. Soodvilai S, Chatsudthipong V, Evans KK, Wright SH, Dantzler WH (2004) Acute regulation of OAT3-mediated estrone sulfate transport in isolated rabbit renal proximal tubules. Am J Physiol Renal Physiol 287(5):F1021–F1029

    Article  CAS  PubMed  Google Scholar 

  12. Hubner G, Sander O, Degner FL, Turck D, Rau R (1997) Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol 24(5):845–851

    CAS  PubMed  Google Scholar 

  13. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS (1999) Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 26(12):2539–2543

    CAS  PubMed  Google Scholar 

  14. Schwartz JI, Agrawal NG, Wong PH, Miller J, Bachmann K, Marbury T, Hoelscher D, Cavanaugh PF Jr, Gottesdiener K (2009) Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol 49(10):1202–1209

    Article  CAS  PubMed  Google Scholar 

  15. Combe B, Edno L, Lafforgue P, Bologna C, Bernard JC, Acquaviva P, Sany J, Bressolle F (1995) Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol 34(5):421–428

    Article  CAS  PubMed  Google Scholar 

  16. Svendsen KB, Ellingsen T, Bech JN, Pfeiffer-Jensen M, Stengaard-Pedersen K, Pedersen EB (2005) Urinary excretion of alpha-GST and albumin in rheumatoid arthritis patients treated with methotrexate or other DMARDs alone or in combination with NSAIDs. Scand J Rheumatol 34(1):34–39

    Article  CAS  PubMed  Google Scholar 

  17. Delanaye P, Cavalier E, Mariat C, Maillard N, Krzesinski JM (2010) MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? BMC Nephrol 11:8

    Article  PubMed Central  PubMed  Google Scholar 

  18. Jung KS, Kim SU, Ahn SH, Park YN, do Kim Y, Park JY, Chon CY, Choi EH, Han KH (2011) Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 53(3):885–894

    Article  CAS  PubMed  Google Scholar 

  19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324

    Article  CAS  PubMed  Google Scholar 

  20. Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome: a new worldwide definition. Lancet 366(9491):1059–1062

    Article  PubMed  Google Scholar 

  21. Lujan PR, Chiurchiu C, Douthat W, de Arteaga J, de la Fuente J, Capra RH, Massari PU (2012) CKD-EPI instead of MDRD for candidates to kidney donation. Transplantation 94(6):637–641

    Article  PubMed  Google Scholar 

  22. Lee SW, Park HJ, Kim BK, Han KH, Lee SK, Kim SU, Park YB (2012) Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther 14(5):R232

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Kang YS, Han KH, Han SY, Kim HK, Cha DR (2005) Characteristics of population with normal serum creatinine impaired renal function and: the validation of a MDRD formula in a healthy general population. Clin Nephrol 63(4):258–266

    Article  CAS  PubMed  Google Scholar 

  24. Kim SU, Choi GH, Han WK, Kim BK, Park JY, do Kim Y, Choi JS, Yang SC, Choi EH, Ahn SH, Han KH, Chon CY (2010) What are ‘true normal’ liver stiffness values using FibroScan? a prospective study in healthy living liver and kidney donors in South Korea. Liver Int 30(2):268–274

    Article  CAS  PubMed  Google Scholar 

  25. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, Sugiyama Y (2007) Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322(3):1162–1170

    Article  CAS  PubMed  Google Scholar 

  26. Maeda A, Tsuruoka S, Kanai Y, Endou H, Saito K, Miyamoto E, Fujimura A (2008) Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur J Pharmacol 596(1–3):166–172

    Article  CAS  PubMed  Google Scholar 

  27. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG (2007) Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 320(1):229–235

    Article  CAS  PubMed  Google Scholar 

  28. Stevens LA, Levey AS (2009) Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 20(11):2305–2313

    Article  PubMed  Google Scholar 

  29. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, Levey AS (2007) Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 18(10):2749–2757

    Article  PubMed  Google Scholar 

  30. Park SH, Choe JY, Kim SK (2010) Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine 77(6):588–592

    Article  CAS  PubMed  Google Scholar 

  31. Barbero-Villares A, Mendoza Jimenez-Ridruejo J, Taxonera C, Lopez-Sanroman A, Pajares R, Bermejo F, Perez-Calle JL, Mendoza JL, Algaba A, Moreno-Otero R, Mate J, Gisbert JP (2012) Evaluation of liver fibrosis by transient elastography (Fibroscan(R)) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 47(5):575–579

    Article  CAS  PubMed  Google Scholar 

  32. Stamp LK, O’Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML (2009) Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 60(8):2248–2256

    Article  CAS  PubMed  Google Scholar 

  33. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, Kremer J (2005) Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 64(8):1180–1185

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflicts of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea

    Hee-Jin Park, Min-Chan Park, Yong-Beom Park, Soo-Kon Lee & Sang-Won Lee

Authors
  1. Hee-Jin Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min-Chan Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong-Beom Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Soo-Kon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sang-Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sang-Won Lee.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 409 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, HJ., Park, MC., Park, YB. et al. The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis. Rheumatol Int 34, 833–840 (2014). https://doi.org/10.1007/s00296-013-2920-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-013-2920-z

Keywords

Search

Navigation